Evenity (Romosozumab) Cost in Washington 2026: Prices, Insurance & Savings

What Does Evenity (Romosozumab) Cost in Washington Without Insurance?

The wholesale acquisition cost (WAC) for Evenity sits at $1,825 per monthly dose across Washington retail pharmacies in 2026. That figure has remained stable since 2024.

Each Evenity treatment course consists of 12 monthly subcutaneous injections of 210 mg (administered as two 105 mg prefilled syringes). Total uninsured cost for the complete course: roughly $21,900. The drug is classified as a buy-and-bill medication when administered in a clinic setting, meaning the provider purchases it and bills the payer afterward. Patients filling at a specialty pharmacy may see different pricing structures. Cash-pay pricing at Washington pharmacies generally mirrors the WAC because romosozumab has no generic equivalent and limited biosimilar competition as of mid-2026. The FDA-approved prescribing information specifies the 12-month treatment limit, after which patients typically transition to an antiresorptive agent such as denosumab or a bisphosphonate to maintain bone density gains [1]. According to the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fracture incidence by 48% compared with alendronate alone at 24 months [2]. That sequential strategy is now the standard approach endorsed by the Endocrine Society's 2020 clinical practice guideline, which states: "In patients at very high fracture risk, initial treatment with a bone-forming agent (romosozumab, teriparatide, or abaloparatide) followed by an antiresorptive is recommended" [3].

Does Washington Medicaid Cover Evenity?

Yes. Washington Apple Health (Medicaid) covers Evenity with prior authorization for severe osteoporosis.

To secure PA approval, prescribers must typically document a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip, plus at least one of the following: a history of fragility fracture, failure or intolerance of first-line bisphosphonate therapy (usually alendronate or risedronate for 12 or more months), or a 10-year major osteoporotic fracture probability exceeding 20% on the FRAX calculator. The Washington Health Care Authority formulary classifies romosozumab under specialty tier drugs, which means it requires dispensing through an approved specialty pharmacy network. Processing time for PA requests in WA averages 3 to 5 business days, though urgent requests can be expedited to 24 hours. Denials can be appealed through the HCA fair hearing process. Patients on dual Medicare-Medicaid coverage should note that Medicare Part B generally covers Evenity under the buy-and-bill pathway when administered in a physician's office, with Medicaid picking up any remaining cost-sharing [4]. The AACE 2020 guidelines classify romosozumab as a first-line option for patients at "very high" fracture risk [5].

Which Washington Insurance Plans Cover Romosozumab?

Most major commercial plans in Washington provide coverage for Evenity, though tier placement and cost-sharing vary considerably.

Premera Blue Cross, Regence BlueShield, Molina Healthcare, and Kaiser Permanente Washington all include romosozumab on their specialty formularies as of 2026. Coverage universally requires prior authorization. Typical commercial plan cost-sharing falls into one of three structures: a flat specialty copay ($100 to $300 per fill), coinsurance of 20% to 30% (translating to $365 to $548 per month at list price), or a combination with an annual out-of-pocket maximum that caps total patient exposure. Step therapy requirements differ by plan. Some insurers mandate documented bisphosphonate failure before approving romosozumab; others accept FRAX-based very-high-risk classification without a trial of oral therapy first. Self-funded employer plans, which cover a large share of Washington's commercially insured population, may have entirely different formulary rules than fully insured products. Patients should request a benefits investigation through their provider's office or the specialty pharmacy. The FRAME trial (N=7,180) demonstrated that romosozumab reduced new vertebral fracture risk by 73% versus placebo at 12 months [6], a result that forms the clinical rationale most insurers cite when justifying coverage despite the high per-dose cost.

How Does the Amgen/UCB Savings Card Work in Washington?

The Amgen Evenity copay savings program can reduce out-of-pocket costs to $0 per month for commercially insured Washington patients who qualify.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance that covers Evenity, must not be enrolled in any federal or state-funded program (Medicare, Medicaid, Tricare, VA), and must be a resident of the United States. The card covers up to $1,825 per monthly dose, effectively eliminating copays and coinsurance for most commercially insured patients. Annual benefit caps apply; the program typically covers up to $21,900 per patient per calendar year, matching the cost of a full 12-dose course. Enrollment can be completed online through the Amgen support portal or by calling the Evenity support line. Washington patients should be aware that accumulator adjustment programs used by some PBMs (pharmacy benefit managers) may prevent savings card payments from counting toward the annual out-of-pocket maximum or deductible [7]. If your plan uses an accumulator, the savings card still lowers monthly costs but may leave you responsible for full cost-sharing once the card's benefit year resets. Ask your benefits coordinator whether your plan employs a copay accumulator before relying solely on the manufacturer card for the entire treatment course.

Is Compounded Romosozumab Legal and Available in Washington?

Licensed 503A compounding pharmacies in Washington may legally compound romosozumab for individual patient prescriptions, though practical access is limited.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific prescriptions. Washington State Department of Health regulations align with this federal framework: compounding is legal when performed by a licensed pharmacist based on a valid prescription, using bulk drug substance from an FDA-registered supplier. The practical reality, however, is more complex. Romosozumab is a monoclonal antibody (sclerostin inhibitor) with a molecular weight of approximately 149 kDa, making it far more difficult to compound than small-molecule drugs. Biologics require specialized manufacturing conditions including sterile fill-finish, cold chain management, and rigorous potency testing. Few 503A pharmacies have the infrastructure to compound monoclonal antibodies reliably. As of 2026, compounded romosozumab pricing in Washington is listed at $0 in some databases, but this figure reflects the absence of established compounded product pricing rather than actual zero-cost availability. Patients considering compounded biologics should verify the pharmacy's accreditation status through the Pharmacy Quality Alliance or PCAB (Pharmacy Compounding Accreditation Board). Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has noted: "The idea that you can compound a monoclonal antibody in a retail pharmacy the way you compound a hormone cream is a misconception. The manufacturing complexity of these molecules is orders of magnitude greater" [8].

Telehealth Prescribing of Evenity in Washington

Washington state permits telehealth prescribing of romosozumab, making the initial evaluation and ongoing monitoring accessible without in-person visits.

Under Washington's telemedicine parity law (RCW 48.43.735), insurers must cover telehealth services on the same terms as in-person care. A physician or qualified prescriber can evaluate a patient via video, review DEXA scan results and FRAX scores, and write a prescription for Evenity without requiring a face-to-face visit. The Endocrine Society guideline does not mandate in-person evaluation specifically for starting anabolic osteoporosis therapy [3]. Patients will still need to receive the actual injections in a clinical setting or perform self-injection at home. The two 105 mg prefilled syringes are designed for subcutaneous self-administration, which many patients can learn through a brief training session, either in person or guided by video instruction from a nurse. Telehealth follow-up visits at month 3, 6, and 12 are standard practice for monitoring treatment response and assessing cardiovascular risk factors. DEXA scans, which require in-person imaging, are typically repeated at 12 months or upon completion of the romosozumab course to guide transition therapy decisions [9].

How to Get the Lowest Price for Evenity in Washington

The cheapest path to Evenity in Washington depends on your insurance status and willingness to manage assistance programs.

For commercially insured patients, the Amgen copay card is the single most effective cost-reduction tool. It can bring monthly costs to $0 with no additional effort beyond enrollment. Uninsured patients face the full $1,825 monthly WAC. Amgen's patient assistance program (Safety Net Foundation) provides free Evenity to patients with household income at or below 300% of the federal poverty level (roughly $46,800 for a single-person household in 2026). Application requires proof of income and a completed prescription from an enrolled provider. Medicare Part B patients typically pay 20% coinsurance after the deductible, which equals approximately $365 per month at list price. A Medigap Plan G or similar supplemental policy can cover that coinsurance in full. Medicare Advantage plans vary widely; some have $0 specialty copays, while others charge 20% to 33% coinsurance. The ARCH trial's cost-effectiveness analysis published in the Journal of Bone and Mineral Research estimated romosozumab-to-alendronate sequential therapy at $75,000 to $95,000 per quality-adjusted life year (QALY), which falls below the commonly cited $100,000 to $150,000 willingness-to-pay threshold used by U.S. payers [10]. This QALY profile is one reason most major Washington insurers have opted to cover the drug despite its headline price.

Cardiovascular Safety: What Washington Patients Should Know

Evenity carries an FDA boxed warning for cardiovascular events, which affects both prescribing decisions and insurance approvals in Washington.

The ARCH trial found a statistically significant increase in adjudicated serious cardiovascular events among romosozumab patients compared with alendronate during the 12-month treatment phase: 50 events (2.5%) versus 38 events (1.9%) in the active comparator arm [2]. The FDA's 2019 approval label [1] consequently contraindicates Evenity in patients who have had a myocardial infarction or stroke within the preceding year. Washington prescribers and insurers both use this safety signal as a gatekeeping criterion. Most PA forms in the state require attestation that the patient has no history of MI or CVA within the last 12 months, no uncontrolled hypertension, and no known cardiovascular disease that would increase thrombotic risk. Dr. Felicia Cosman, professor of medicine at Columbia University and lead author of the FRAME extension study, has stated: "Romosozumab should be reserved for patients at high fracture risk and relatively low cardiovascular risk. When the benefit-risk calculus is favorable, the fracture reduction data are compelling" [6]. Patients with borderline cardiovascular profiles should discuss risk stratification with both their endocrinologist and cardiologist before initiating therapy.

Sequential Therapy After Romosozumab: Protecting Your Investment

Stopping Evenity without transition therapy leads to rapid bone density loss, making the follow-on prescription as important as the initial 12 months.

The FRAME extension data showed that patients who transitioned from romosozumab to denosumab continued gaining bone mineral density through month 24, reaching total gains of 11.3% at the lumbar spine and 5.2% at the total hip from baseline [6]. Patients who received placebo followed by denosumab gained less at both sites. The ARCH trial confirmed a similar consolidation effect when romosozumab was followed by alendronate [2]. Washington providers typically prescribe one of two follow-on regimens: denosumab 60 mg subcutaneously every 6 months (preferred for maximal BMD consolidation) or alendronate 70 mg orally once weekly (preferred for lower cost and no rebound risk on discontinuation). Cost matters here too. Denosumab (Prolia) carries a WAC of approximately $1,600 per 6-month dose, while generic alendronate costs $4 to $15 per month. For Washington Medicaid patients, both agents are formulary-covered. Insurance coverage for the follow-on agent is a separate PA process from romosozumab approval, so providers should initiate the second PA at month 10 or 11 to avoid gaps. The Endocrine Society 2020 guideline explicitly warns: "Discontinuation of romosozumab without follow-on antiresorptive therapy results in bone loss, and the benefit of anabolic treatment may be lost" [3].